Dermatologist preferences for first-line therapy of moderate to severe psoriasis in healthy adult patients

Journal of the American Academy of Dermatology

Volumn 66, Issue 3, 2012, Pages 376-386

  Wan, Joy ^a,b,d,e   Abuabara, Katrina ^a,b,d,e   Troxel, Andrea B ^a,b,d,e   Shin, Daniel B ^a,b,d,e   Van Voorhees, Abby S ^a,b,d,e   Bebo Jr , Bruce F ^b,d,e   Krueger, Gerald G ^b,c,d,e   Callis Duffin, Kristina ^c,d,e   Gelfand, Joel M ^a,d,e  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b National Psoriasis Foundation   (United States)

^c UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e NONE

Author keywords

biologic; comparative effectiveness; methotrexate; phototherapy; psoriasis; treatment preference; tumor necrosis factor inhibitor

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN A; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE; PSORALEN; USTEKINUMAB;

ADULT; ARTICLE; CLINICAL PRACTICE; DERMATOLOGIST; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; PHOTOTHERAPY; PREGNANCY; PRIORITY JOURNAL; PSORIASIS; TREATMENT OUTCOME; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; VIGNETTE;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ATTITUDE OF HEALTH PERSONNEL; DERMATOLOGY; FEMALE; HEALTH CARE SURVEYS; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; PROFESSIONAL PRACTICE; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; ULTRAVIOLET THERAPY;

EID: 84857451600     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2011.03.012     Document Type: Article

References (38)

1. R.S. Stern, T. Nijsten, S.R. Feldman, D.J. Margolis, and T. Rolstad Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction J Investig Dermatol Symp Proc 9 2004 136 139 (Pubitemid 38457271)
2. S.K. Kurd, and J.M. Gelfand The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004 J Am Acad Dermatol 60 2009 218 224
3. C.E. Griffiths, and J.N. Barker Pathogenesis and clinical features of psoriasis Lancet 370 2007 263 271 (Pubitemid 47069537)
4. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741 (Pubitemid 44547793)
5. J.M. Gelfand, A.B. Troxel, J.D. Lewis, S.K. Kurd, D.B. Shin, and X. Wang The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 143 2007 1493 1499 (Pubitemid 350277763)
6. K. Abuabara, R.S. Azfar, D.B. Shin, A.L. Neimann, A.B. Troxel, and J.M. Gelfand Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the UK Br J Dermatol 163 2010 586 592
7. U. Chaudhari, P. Romano, L.D. Mulcahy, L.T. Dooley, D.G. Baker, and A.B. Gottlieb Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomized trial Lancet 357 2001 1842 1847 (Pubitemid 32539117)
8. C.N. Ellis, and G.G. Krueger Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes N Engl J Med 345 2001 248 255 (Pubitemid 32695064)
9. C.L. Leonardi, J.L. Powers, R.T. Matheson, B.S. Goffe, R. Zitnik, and A. Wang Etanercept as monotherapy in patients with psoriasis N Engl J Med 349 2003 2014 2022 (Pubitemid 37448924)
10. C.L. Leonardi, A.B. Kimball, K.A. Papp, N. Yeilding, C. Guzzo, and Y. Wang Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 1) Lancet 371 2008 1665 1674 (Pubitemid 351671883)
11. A. Menter, S.K. Tyring, K. Gordon, A.B. Kimball, C.L. Leonardi, and R.G. Langley Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial J Am Acad Dermatol 58 2008 106 115 (Pubitemid 350298146)
12. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850 (Pubitemid 351509656)
13. A. Menter, N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents J Am Acad Dermatol 61 2009 451 485
14. A. Menter, N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy J Am Acad Dermatol 62 2010 114 135
15. D. Pathirana, A.D. Ormerod, P. Saiag, C. Smith, P.I. Spuls, and A. Nast European S3-guidelines on the systemic treatment of psoriasis vulgaris J Eur Acad Dermatol Venereol 23 Suppl 2009 1 70
16. A.S. Van Voorhees, S.R. Feldman, J.Y. Koo, M.G. Lebwohl, and A. Menter The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options 2009 National Psoriasis Foundation Portland (OR)
17. C.H. Smith, A.V. Anstey, J.N. Barker, A.D. Burden, R.J. Chalmers, and D. Chandler British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005 Br J Dermatol 153 2005 486 497 (Pubitemid 41248202)
18. A. Nast, I.B. Kopp, M. Augustin, K.B. Banditt, W.H. Boehncke, and M. Follmann Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris J Dtsch Dermatol Ges 5 Suppl 2007 1 119 (Pubitemid 47033875)
19. Institute of Medicine Initial national priorities for comparative effectiveness research 2009 National Academies Press Washington (DC)
20. J.W. Peabody, J. Luck, P. Glassman, T.R. Dresselhaus, and M. Lee Comparison of vignettes, standardized patients, and chart abstraction: a prospective validation study of 3 methods for measuring quality JAMA 283 2000 1715 1722 (Pubitemid 30196212)
21. J.W. Peabody, J. Luck, P. Glassman, S. Jain, J. Hansen, and M. Spell Measuring the quality of physician practice by using clinical vignettes: a prospective validation study Ann Intern Med 141 2004 771 780
22. J. Veloski, S. Tai, A.S. Evans, and D.B. Nash Clinical vignette-based surveys: a tool for assessing physician practice variation Am J Med Qual 20 2005 151 157 (Pubitemid 40880390)
23. D.A. Dillman Mail and telephone surveys: the total design method 1978 Wiley New York
24. D.A. Dillman Mail and Internet surveys: the tailored design method 2000 J Wiley New York
25. J. Wan, K. Abuabara, D.B. Shin, A.B. Troxel, B.F. Bebo Jr., and J.M. Gelfand Dermatologist response rates to a mailed questionnaire: a randomized trial of monetary incentives J Am Acad Dermatol 66 2012 e18 e20
26. E. von Elm, D.G. Altman, M. Egger, S.J. Pocock, P.C. Gotzsche, and J.P. Vandenbroucke The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies J Clin Epidemiol 61 2008 344 349 (Pubitemid 351289042)
27. T.S. Housman, J.M. Rohrback, A.B. Fleischer Jr., and S.R. Feldman Phototherapy utilization for psoriasis is declining in the United States J Am Acad Dermatol 46 2002 557 559
28. G.L. Simpson, C.B. Yelverton, S. Rittenberg, and S.R. Feldman Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat 17 2006 359 361 (Pubitemid 46895583)
29. J. Sariego Regional variation in breast cancer treatment throughout the United States Am J Surg 196 2008 572 574
30. H.M. Krumholz, J. Chen, S.S. Rathore, Y. Wang, and M.J. Radford Regional variation in the treatment and outcomes of myocardial infarction: investigating New England's advantage Am Heart J 146 2003 242 249 (Pubitemid 36951767)
31. E.D. Dommasch, K. Abuabara, D.B. Shin, J. Nguyen, A.B. Troxel, and J.M. Gelfand The risk of infection and malignancy with tumor necrosis factor antagonists in adult patients with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials J Am Acad Dermatol 64 2011 1035 1050
32. J. Schmitt, Z. Zhang, G. Wozel, M. Meurer, and W. Kirch Efficacy and tolerability of biologic and nonbiologic systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials Br J Dermatol 159 2008 513 526
33. T.V. Perneger What's wrong with Bonferroni adjustments BMJ 316 1998 1236 1238 (Pubitemid 28171344)
34. D.A. Savitz, and A.F. Olshan Describing data requires no adjustment for multiple comparisons: a reply from Savitz and Olshan Am J Epidemiol 147 1998 813 814 (Pubitemid 128721155)
35. I. Flytstrom, B. Stenberg, A. Svensson, and I.M. Bergbrant Methotrexate vs ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial Br J Dermatol 158 2008 116 121 (Pubitemid 350221914)
36. C.E. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, and N. Yeilding Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
37. V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Borgie, J.B. Reitsma, and W.F. Goldschmidt Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665 (Pubitemid 36975998)
38. J.H. Saurat, G. Stingl, L. Dubertret, K. Papp, R.G. Langley, and J.P. Ortonne Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs placebo in patients with psoriasis (CHAMPION) Br J Dermatol 158 2008 558 566 (Pubitemid 351239154)